Subscribe
Nicholas Fox, partner at Mathys & Squire
30 August 2024NewsEuropeLiz Hockley

UK firm prevails in ‘exceptionally slow’ UPC test case

Court grants access to test case documents after eight months | Mathys & Squire applied for access to challenge UPC's transparency | Firm says "significant concerns" remain about the court's commitment to transparency and open justice.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Why the UPC will be rewarding for US businesses
4 April 2023   Pinsent Masons and Sterne, Kessler, Goldstein, & Fox consider why the Unified Patent Court, due to open on June 1, 2023, will make Europe a more attractive patent litigation venue for US businesses.
Big Pharma
UPC confirms dates for 10x Genomics hearings
22 August 2023   UPC announces public hearings at Munich court | Proceedings relate to the dispute over patents covering the in-situ detection of analytes.
Biotechnology
UPC Court of Appeal revokes NanoString injunction in first substantive decision
27 February 2024   UPC overturns previous decision barring NanoString from selling CosMx products in 17 European countries | Court did not stay proceedings on account of NanoString’s Chapter 11 filing.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Americas
Why the UPC will be rewarding for US businesses
4 April 2023   Pinsent Masons and Sterne, Kessler, Goldstein, & Fox consider why the Unified Patent Court, due to open on June 1, 2023, will make Europe a more attractive patent litigation venue for US businesses.
Big Pharma
UPC confirms dates for 10x Genomics hearings
22 August 2023   UPC announces public hearings at Munich court | Proceedings relate to the dispute over patents covering the in-situ detection of analytes.
Biotechnology
UPC Court of Appeal revokes NanoString injunction in first substantive decision
27 February 2024   UPC overturns previous decision barring NanoString from selling CosMx products in 17 European countries | Court did not stay proceedings on account of NanoString’s Chapter 11 filing.

More on this story

Americas
Why the UPC will be rewarding for US businesses
4 April 2023   Pinsent Masons and Sterne, Kessler, Goldstein, & Fox consider why the Unified Patent Court, due to open on June 1, 2023, will make Europe a more attractive patent litigation venue for US businesses.
Big Pharma
UPC confirms dates for 10x Genomics hearings
22 August 2023   UPC announces public hearings at Munich court | Proceedings relate to the dispute over patents covering the in-situ detection of analytes.
Biotechnology
UPC Court of Appeal revokes NanoString injunction in first substantive decision
27 February 2024   UPC overturns previous decision barring NanoString from selling CosMx products in 17 European countries | Court did not stay proceedings on account of NanoString’s Chapter 11 filing.

More features

Novartis shields eye-drop patent at European Patent Office
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York
UPC deals further blow to Dexcom in glucose monitor dispute with Abbott
‘A marathon and a sprint at the same time’: How we won $452m damages
Judge denies Intellia bid to throw out suit over $100m Regeneron pact